Form 4: Heron Therapeutics CEO Craig Collard Reports Stock Transaction
SEC Form 4 Filing
CEO Craig Collard reports the vesting of restricted stock units and acquisition of common stock.
Summary
- On April 3, 2025, Craig Collard, the CEO of Heron Therapeutics, reported a transaction involving restricted stock units.
- 62,500 restricted stock units vested, converting into 62,500 shares of common stock.
- Following the transaction, Collard directly owns 377,367 shares of Heron Therapeutics common stock.
- Collard also directly owns 125,000 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine insider transaction filing, neither particularly positive nor negative.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the vesting of previously granted compensation.
Stakeholder Impact
- The transaction increases the CEO's stake in the company, potentially aligning his interests further with shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/03/2025 | Date of transaction: vesting of restricted stock units and acquisition of common stock. |
Keywords
Form 4, insider trading, stock transaction, restricted stock units, Craig Collard, Heron Therapeutics, HRTX, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.